Novavax (NVAX) Retained Earnings (2010 - 2026)
Novavax (NVAX) posted quarterly Retained Earnings of $4.5 billion for Q1 2026, up 0.79% year-over-year from $4.5 billion in Q1 2025, and up 199.57% quarter-over-quarter from -$4.6 billion in Q4 2025.
Novavax (NVAX) Retained Earnings (2010 - 2026) Analysis & Trends
Novavax's Retained Earnings history runs 17 years deep, the most recent figure standing at $4.5 billion for Q1 2026.
- In Q1 2026, Retained Earnings rose 0.79% year-over-year to $4.5 billion; the TTM figure through Mar 2026 stood at $4.5 billion (up 0.79% YoY), while the FY2025 annual figure was -$4.6 billion, up 8.79% from the prior year.
- Retained Earnings for Q1 2026 stood at $4.5 billion, up from -$4.6 billion in the prior quarter.
- The five-year high for Retained Earnings was $4.5 billion in Q1 2026, with the low at -$5.0 billion in Q4 2024.
- The 5-year median for Retained Earnings is $3.6 billion (2022), against an average of $802.7 million.
- The sharpest annual moves came in 2022 and 2023: Retained Earnings plunged 371.32% in 2022, then surged 65838.81% in 2023.
- Novavax's Retained Earnings stood at -$6.4 million in 2022, then soared by 65838.81% to $4.2 billion in 2023, then sank by 219.47% to -$5.0 billion in 2024, then gained by 8.79% to -$4.6 billion in 2025, then jumped by 199.57% to $4.5 billion in 2026.
- Business Quant data shows NVAX's Retained Earnings at $4.5 billion in Q1 2026, -$4.6 billion in Q4 2025, and -$4.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn | -4.63 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.63 Bn |
| Mar 31, 2026 | 4.55 Bn |
| Dec 31, 2025 | -4.57 Bn |
| Sep 30, 2025 | -4.59 Bn |
| Jun 30, 2025 | 4.52 Bn |
| Mar 31, 2025 | 4.51 Bn |
| Dec 31, 2024 | -5.01 Bn |
| Sep 30, 2024 | -4.93 Bn |
| Jun 30, 2024 | 4.48 Bn |
| Mar 31, 2024 | -10.83 Mn |
| Dec 31, 2023 | 4.19 Bn |
| Sep 30, 2023 | 4.07 Bn |
| Jun 30, 2023 | 3.86 Bn |
| Mar 31, 2023 | -4.57 Bn |
| Dec 31, 2022 | -6.38 Mn |
| Sep 30, 2022 | -23.79 Mn |
| Jun 30, 2022 | 3.60 Bn |
| Mar 31, 2022 | 3.57 Bn |
| Dec 31, 2021 | -1.35 Mn |
| Sep 30, 2021 | 3.31 Bn |